For decades, administrations have released selected results from presidential physicals, offering the public a glimpse at the commander-in-chief’s health. But the results are filtered through the ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics ...

Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost ...

SAN MATEO, Calif. — Peyton Greenside, CEO of BigHat Biosciences, has hot takes. Her company designs antibody therapies using machine-learning, but she doesn’t like demos in which people open their ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — A group of Senate ...

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable showdown with ...

The company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.

In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the ...

Far fewer knew that mpox and Zika can also be transmitted sexually. And most respondents understood the main ways that these ...

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.